Plain-English translation of NCT06535308 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Alzheimer Disease research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called BnH-015B designed to help people with Alzheimer's disease. Researchers will give different doses of the medication to healthy volunteers first to make sure it's safe, and then to people with moderate Alzheimer's disease to see how their bodies handle it. The trial will also look at whether food affects how the medication works.
Current Alzheimer's treatments only temporarily ease symptoms and don't stop the disease from progressing. This trial exists to find out if this medication could offer a new treatment option for patients who need better solutions.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
The trial has two parts. In Part I, healthy volunteers receive single doses of the medication at increasing strengths, and some take it with food to see if meals affect how it works. In Part II, people with moderate Alzheimer's disease receive either the medication or a placebo in multiple doses over time. Participants will have regular visits for medical check-ups, blood draws, and tests to measure how their body handles the medication and whether it affects their cognitive function.
AI-generated summary from trial data ยท Jun 10, 2026 ยท Not medical advice
South Korea